Literature DB >> 8547163

GEDNAP IV and V. The 4th and 5th Stain Blind Trials using DNA technology.

P Wiegand1, E Ambach, C Augustin, H Bratzke, U Cremer, J Edelmann, B Eriksen, U Germann, H Haas, L Henke.   

Abstract

In the collaborative exercise GEDNAP IV one EDTA blood sample (2 ml) and 5 bloodstains (0.5 ml on cotton) were investigated and in GEDNAP V, a total of 8 bloodstains (0.5 ml on cotton), including 2 mixed bloodstains. DNA typing was carried out using the RFLP systems YNH24/Hinf I and MS43a/Hinf I and the PCR systems HLA DQ alpha, D1S80, ApoB and YNZ22. In both exercises approximately 20 laboratories obtained results using the RFLP systems. Of the PCR systems, D1S80 was the most commonly used (14 labs in GEDNAP IV; 18 labs in GEDNAP V). The interlaboratory standard deviation for YNH24 in both exercises was approx. 0.6%, for MS43a 0.7-2.2% (GEDNAP IV) and 0.4-1.4% (GEDNAP V), depending on the fragment size. The fragment size calculation performed in each laboratory yielded a standard deviation twice that obtained when the fragment size calculation was performed centrally (IfR, Münster). In GEDNAP III, a system-specific corridor was developed to define the limits of deviation; this was modified for the present study by combining the fragment size ranges of YNH24 and MS43a. In both studies a subgroup of laboratories was involved in preliminary exercises using three PCR VNTRs and the system HLA DQ alpha. Owing to the substantial variation in experience of the participating laboratories with PCR typing the results obtained in these two studies do not fulfil the basic quality criteria of the GEDNAP studies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8547163     DOI: 10.1007/bf01369909

Source DB:  PubMed          Journal:  Int J Legal Med        ISSN: 0937-9827            Impact factor:   2.686


  9 in total

1.  DNA extraction from mixtures of body fluid using mild preferential lysis.

Authors:  P Wiegand; M Schürenkamp; U Schütte
Journal:  Int J Legal Med       Date:  1992       Impact factor: 2.686

2.  Use of formamide to improve amplification of HLA DQ alpha sequences.

Authors:  C T Comey; J M Jung; B Budowle
Journal:  Biotechniques       Date:  1991-01       Impact factor: 1.993

3.  Report of a European collaborative exercise comparing DNA typing results using a single locus VNTR probe.

Authors:  P M Schneider; R Fimmers; S Woodroffe; D J Werrett; W Bär; B Brinkmann; B Eriksen; S Jones; A D Kloosterman; B Mevåg
Journal:  Forensic Sci Int       Date:  1991 Jan-Feb       Impact factor: 2.395

4.  A report of an international collaborative experiment to demonstrate the uniformity obtainable using DNA profiling techniques.

Authors:  P Gill; S Woodroffe; W Bär; B Brinkmann; A Carracedo; B Eriksen; S Jones; A D Kloosterman; B Ludes; B Mevag
Journal:  Forensic Sci Int       Date:  1992-02       Impact factor: 2.395

5.  Analysis of the VNTR locus D1S80 by the PCR followed by high-resolution PAGE.

Authors:  B Budowle; R Chakraborty; A M Giusti; A J Eisenberg; R C Allen
Journal:  Am J Hum Genet       Date:  1991-01       Impact factor: 11.025

Review 6.  Sequence-directed curvature of DNA.

Authors:  P J Hagerman
Journal:  Annu Rev Biochem       Date:  1990       Impact factor: 23.643

7.  Rapid typing of tandemly repeated hypervariable loci by the polymerase chain reaction: application to the apolipoprotein B 3' hypervariable region.

Authors:  E Boerwinkle; W J Xiong; E Fourest; L Chan
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

8.  Amplification of a highly polymorphic VNTR segment by the polymerase chain reaction.

Authors:  G T Horn; B Richards; K W Klinger
Journal:  Nucleic Acids Res       Date:  1989-03-11       Impact factor: 16.971

9.  Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes.

Authors:  R K Saiki; P S Walsh; C H Levenson; H A Erlich
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

  9 in total
  1 in total

1.  The GEDNAP blind trial concept part II. Trends and developments.

Authors:  S Rand; M Schürenkamp; C Hohoff; B Brinkmann
Journal:  Int J Legal Med       Date:  2004-01-31       Impact factor: 2.686

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.